16,308 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by HighPoint Advisor Group LLC

Posted by Francis Steltz on May 15th, 2026

HighPoint Advisor Group LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund acquired 16,308 shares of the company’s stock, valued at approximately $509,000.

Several other institutional investors have also recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Phoenix Financial Ltd. raised its holdings in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after acquiring an additional 427,000 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after acquiring an additional 4,820,000 shares during the last quarter. Finally, Rubric Capital Management LP raised its holdings in Teva Pharmaceutical Industries by 1.8% in the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after acquiring an additional 450,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 2.5%

TEVA stock opened at $35.33 on Friday. The company has a market cap of $40.62 billion, a price-to-earnings ratio of 26.56, a PEG ratio of 3.51 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The business has a fifty day simple moving average of $31.51 and a 200-day simple moving average of $30.40. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion during the quarter. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Insider Activity

In related news, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the sale, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This represents a 25.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Savage sold 1,127 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the sale, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,127,018 shares of company stock worth $37,298,712 in the last quarter. Insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Scotiabank boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Read Our Latest Report on TEVA

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.